To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period
An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy in Male and Female with Androgenetic Alopecia Treated with HMI-115 Over a 24-Week Treatment Period
In the register
The register attaches this trial to HMI-115 (Hope Medicine), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 1
- Sponsor
- Hope Medicine (Nanjing) Co., Ltd
- Participants (registry)
- 16
- Start
- May 2022
- Primary completion
- September 2023
- Study completion
- September 2023
- Last registry update
- September 2024
- Countries
- Australia
Conditions studied: Androgenetic Alopecia
Interventions: HMI-115
Other trials of HMI-115
A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.